- Home
- MRVL vs REGN Comparison
MRVL vs REGN Comparison
Compare MRVL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVL
- REGN
- Stock Information
- Founded
- MRVL 1995
- REGN 1988
- Country
- MRVL United States
- REGN United States
- Employees
- MRVL N/A
- REGN N/A
- Industry
- MRVL Semiconductors
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- MRVL Technology
- REGN Health Care
- Exchange
- MRVL Nasdaq
- REGN Nasdaq
- Market Cap
- MRVL 53.0B
- REGN 63.4B
- IPO Year
- MRVL 2000
- REGN 1991
- Fundamental
- Price
- MRVL $77.70
- REGN $541.75
- Analyst Decision
- MRVL Strong Buy
- REGN Buy
- Analyst Count
- MRVL 29
- REGN 22
- Target Price
- MRVL $100.66
- REGN $839.91
- AVG Volume (30 Days)
- MRVL 24.0M
- REGN 1.3M
- Earning Date
- MRVL 05-29-2025
- REGN 08-01-2025
- Dividend Yield
- MRVL 0.32%
- REGN 0.66%
- EPS Growth
- MRVL N/A
- REGN 16.49
- EPS
- MRVL N/A
- REGN 39.43
- Revenue
- MRVL $6,501,700,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- MRVL $45.77
- REGN N/A
- Revenue Next Year
- MRVL $17.99
- REGN $6.78
- P/E Ratio
- MRVL N/A
- REGN $13.56
- Revenue Growth
- MRVL 21.60
- REGN 7.52
- 52 Week Low
- MRVL $47.09
- REGN $476.49
- 52 Week High
- MRVL $127.48
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- MRVL 63.00
- REGN 54.42
- Support Level
- MRVL $75.04
- REGN $514.79
- Resistance Level
- MRVL $81.12
- REGN $548.04
- Average True Range (ATR)
- MRVL 2.91
- REGN 13.58
- MACD
- MRVL 0.36
- REGN 5.33
- Stochastic Oscillator
- MRVL 75.83
- REGN 85.96
About MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).